DBVT News and Press, DBV Technologies S.A. From 06/26/19

Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer   Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to continue serving as Chief Scientific Officer DBV Technol...

Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of Viaskin ® Peanut   DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Sto...

Montrouge, France, May 24, 2019 DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR...

One, which I mention several times elsewhere, is the need for patience if big profits are to be made from investment. Put another way, it is often easier to tell what will happen to the price of a stock than how much time will elapse before it happens. The other is the inherently deceptive ...

DBV Technologies' (NASDAQ: DBVT ) Deputy CEO and Principal Financial Officer, David Schilansky, has decided to leave the company to pursue other professional opportunities. More news on: DBV Technologies S.A., DBV Technologies S.A., Healthcare stocks news, Read more ...

Montrouge, France, May 14, 2019 DBV Technologies Announces Departure of Deputy CEO David Schilansky DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its Deputy Chief Executiv...

Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced toda...

Montrouge, France, April 30, 2019 DBV Technologies Reports March 31, 2019 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and cash equivalents as of March 31,...

                                                                                  &#x...

Montrouge, France, April 8, 2019 DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an underwritten global offering of an ...